Relapsed or Refractory Mantle Cell Lymphoma: Available and Emerging Therapies
DOI:
https://doi.org/10.58931/cht.2024.3356Abstract
Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma (NHL) that accounts for 5–7% of all NHL. In most cases, it is characterized by t(11;14) leading to cyclin D1 overexpression. MCL displays a heterogeneous clinical behavior, ranging from a very indolent to a very aggressive clinical course. Biological features associated with aggressive disease include morphology (pleomorphic or blastoid), high proliferation index (Ki67 >30%), adverse clinical scores (Mantle Cell Lymphoma International Prognostic Index [MIPIb])3, and TP53 mutation status. Patients who relapse within 24 months of initial treatment (POD24) have a poor prognosis with median overall survival (OS) of approximately 12 months.
Most patients achieve long-term disease control with first-line treatment, which currently involves induction rituximab-containing chemotherapy with or without autologous stem cell transplantation, followed by maintenance rituximab. Trials assessing Bruton tyrosine kinase inhibitors (BTKi) and other novel agents in the first-line setting have been recently published or are ongoing. These options are currently not available in Canada outside of clinical trials but may become standard of care in the future.
Relapse after first-line therapy is inevitable, and curability outside the context of allogeneic stem cell transplant (alloSCT) remains unclear, with most patients eventually requiring second and subsequent lines of therapy. In the last decade, new therapies have changed the treatment landscape of relapsed/refractory (R/R) MCL, and their optimal sequencing or combination remain unclear. Treatment options will be described herein, with a proposed treatment algorithm for R/R MCL (Figure 1).
References
Armitage JO, Longo DL. Mantle-Cell Lymphoma. NEJM. 2022;386(26):2495-506. DOI: https://doi.org/10.1056/NEJMra2202672
Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111(4):2385-7. DOI: https://doi.org/10.1182/blood-2007-10-117010
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-65. DOI: https://doi.org/10.1182/blood-2007-06-095331
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903-10. DOI: https://doi.org/10.1182/blood-2017-04-779736
Simone F, Davide R, Andrea R, Alessio B, Valeria S, Christian WE, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105(6):1604-12. DOI: https://doi.org/10.3324/haematol.2018.214056
Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner A-K, Zilioli VR, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185(5):940-4. DOI: https://doi.org/10.1111/bjh.15643
Bond DA, Switchenko JM, Maddocks KJ, Churnetski MC, Goyal S, Shanmugasundaram K, et al. Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. Blood. 2019;134:753. DOI: https://doi.org/10.1182/blood-2019-128415
Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-89. DOI: https://doi.org/10.1182/bloodadvances.2021004765
Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, et al. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Adv. 2023;7(16):4576-85. DOI: https://doi.org/10.1182/bloodadvances.2023009804
Villa D, Sehn LH, Savage KJ, Toze CL, Song K, den Brok WD, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020;4(15):3486-94. DOI: https://doi.org/10.1182/bloodadvances.2020002068
Tessoulin B, Chiron D, Thieblemont C, Oberic L, Bouadballah K, Gyan E, et al. Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplant. 2021;56(7):1700-9. DOI: https://doi.org/10.1038/s41409-020-01198-2
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. The Lancet. 2016;388(10044):565-75. DOI: https://doi.org/10.1016/S0140-6736(16)00739-X
Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410-8. DOI: https://doi.org/10.1111/bjh.14241
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2023;21(11):1118-31. DOI: https://doi.org/10.6004/jnccn.2023.0057
Eyre TA, Bishton MJ, McCulloch R, O’Reilly M, Sanderson R, Menon G, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108-26. DOI: https://doi.org/10.1111/bjh.19131
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. NEJM. 2017;377(13):1250-60. DOI: https://doi.org/10.1056/NEJMoa1701769
Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, et al. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica. 2023;108(8):2218-23. DOI: https://doi.org/10.3324/haematol.2022.282252
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024. DOI: https://doi.org/10.1016/S0140-6736(24)00184-3
Villa D, Larouche JF, Cheung M, Keating MM, Zukotynski K, Tonseth P, et al. Rituximab combined with chemotherapy and acalabrutinib prior to autologous stem cell transplantation in mantle cell lymphoma: The Rectangle Trial. Hematol Oncol. 2023;41(S2):483-4. DOI: https://doi.org/10.1002/hon.3164_355
Michael Wang JM, David Belada, Yuqin Song, Wojciech Jurczak, Jonas Paludo, Michael P. Chu, Irina Kryachok, Laura Fogliatto, Chan Cheah, Marta Morawska, Juan Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Martin Dreyling. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024 Late Breaking Abstract. 2024.
Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H, et al. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17(3):255-62. DOI: https://doi.org/10.2217/fon-2020-0794
AstraZeneca. A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse). 2023.
Minson A, Hamad N, Di Ciaccio P, Talaulikar D, Ku M, Ratnasingam S, et al. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. Br J Haematol. 2024;204(2):548-54. DOI: https://doi.org/10.1111/bjh.19179
Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787-95. DOI: https://doi.org/10.1038/s41375-020-01013-3
Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021;56(12):2911-21. DOI: https://doi.org/10.1038/s41409-021-01288-9
Dreyling M, Goy A, Hess G, Kahl BS, Hernández-Rivas J, Schuier N, et al. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Hemasphere. 2022;6(5):e712. DOI: https://doi.org/10.1097/HS9.0000000000000712
Tivey A, Shotton R, Eyre TA, Lewis D, Stanton L, Allchin R, et al. Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study. Blood Adv. 2024;8(5):1209-19. DOI: https://doi.org/10.1182/bloodadvances.2023011152
Dartigeas C, Slama B, Doyle M, Tapprich C, Albrecht C, Dupuis S, et al. FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL. Clin Hematol Int. 2022;4(3):65-74. DOI: https://doi.org/10.1007/s44228-022-00015-5
Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581-4. DOI: https://doi.org/10.1182/blood-2016-10-742437
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. NEJM. 2022;386(26):2482-94. DOI: https://doi.org/10.1056/NEJMoa2201817
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659-67. DOI: https://doi.org/10.1016/S0140-6736(17)33108-2
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase. Clin Cancer Res. 2020;26(16):4216-24. DOI: https://doi.org/10.1158/1078-0432.CCR-19-3703
Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, et al. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J. 2023;13(1):169. DOI: https://doi.org/10.1038/s41408-023-00942-3
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35(8):826-33. DOI: https://doi.org/10.1200/JCO.2016.70.4320
Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68-e71. DOI: https://doi.org/10.3324/haematol.2018.198812
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023;7(13):2983-93. DOI: https://doi.org/10.1182/bloodadvances.2022008916
Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016;35(48):6223-34. DOI: https://doi.org/10.1038/onc.2016.155
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. NEJM. 2018;378(13):1211-23. DOI: https://doi.org/10.1056/NEJMoa1715519
Wang M, Jurczak W, Trněný M, Belada D, Wrobel T, Ghosh N, et al. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. Blood. 2023;142(Supplement 2):LBA-2-LBA-. DOI: https://doi.org/10.1182/blood-2023-191921
Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175-9. DOI: https://doi.org/10.1093/annonc/mdv111
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. NEJM. 2020;382(14):1331-42. DOI: https://doi.org/10.1056/NEJMoa1914347
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594-606. DOI: https://doi.org/10.1200/JCO.22.01797
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606-10. DOI: https://doi.org/10.1182/bloodadvances.2021006922
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study. J Clin Oncol. 2024;42(10):1146-57. DOI: https://doi.org/10.1200/JCO.23.02214
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017;35(13):1437-43. DOI: https://doi.org/10.1200/JCO.2016.70.2282
Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, et al. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol. 2023;16(1):99. DOI: https://doi.org/10.1186/s13045-023-01496-4
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023;41(24):3988-97. DOI: https://doi.org/10.1200/JCO.23.00562
Simmons ME, McIntosh J, Zhang T, Li Y, Yan F, Yao Y, et al. The Reversible BTK Inhibitor Nemtabrutinib Demonstrates Favorable Antitumor Efficacy and Enhances the Function of CAR T Cells in Mantle Cell Lymphoma. Blood. 2023;142:5789. DOI: https://doi.org/10.1182/blood-2023-187405
LLC MSD. A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006). 2024.
Zinzani PL, Mayer J, Benjamini O, Berkovits A, Glimelius I, Stevens DA, et al. waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies. J ClinOncol. 2023;41(16_suppl):TPS7595-TPS. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7595
Kipps TJ. ROR1: an orphan becomes apparent. Blood. 2022;140(14):1583-91. DOI: https://doi.org/10.1182/blood.2021014760
Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14(1):132. DOI: https://doi.org/10.1186/s13045-021-01143-w
Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evidence. 2022;1(1):EVIDoa2100001. DOI: https://doi.org/10.1056/EVIDoa2100001
Phillips TJ, Dickinson M, Morschhauser F, Bachy E, Crump M, Trněný M, et al. Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma. Blood. 2022;140(Supplement 1):178-80. DOI: https://doi.org/10.1182/blood-2022-157777
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. Blood. 2020;136(Supplement 1):45-6. DOI: https://doi.org/10.1182/blood-2020-133820
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon S-S, Yoon DH, et al. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. J Clin Oncol. 2024;0(0):JCO.23.02329.
Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467-80. DOI: https://doi.org/10.1182/blood.2021011994
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024;143(16):1565-75. DOI: https://doi.org/10.1182/blood.2023022432
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med. 2024;30(1):229-39. DOI: https://doi.org/10.1038/s41591-023-02726-5
Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57-66. DOI: https://doi.org/10.1016/S1470-2045(15)00447-7
McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. British journal of haematology. 2020;189(4):684-8. DOI: https://doi.org/10.1111/bjh.16416
Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171. DOI: https://doi.org/10.1186/s13045-017-0537-5
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, Boral A, et al. Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study. Journal of Clinical Oncology. 2006;24(18_suppl):7512-. DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.7512
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology. 2009;20(3):520-5. DOI: https://doi.org/10.1093/annonc/mdn656
Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica. 2017;102(5):e203-e6. DOI: https://doi.org/10.3324/haematol.2016.154211
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739-45. DOI: https://doi.org/10.1182/blood-2015-03-635326
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16. DOI: https://doi.org/10.1056/NEJMoa1306220
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. The Lancet. 2016;387(10020):770-8. DOI: https://doi.org/10.1016/S0140-6736(15)00667-4
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica. 2024;109(1):343-50. DOI: https://doi.org/10.3324/haematol.2022.282469
Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577-85. DOI: https://doi.org/10.1182/bloodadvances.2020004074
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148-58. DOI: https://doi.org/10.1182/blood.2021014162
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023;41(3):555-67. DOI: https://doi.org/10.1200/JCO.21.02370
Wang ML, Assouline S, Kamdar M, Ghosh N, Naik S, Nakhoda SK, et al. Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study. Blood. 2023;142(Supplement 1):734-. DOI: https://doi.org/10.1182/blood-2023-174956
Wang ML, Mei M, Barr PM, Barrientos JC, de Vos S, Furman RR, et al. Zilovertamab vedotin (MK-2140) in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): 14-month follow-up of the phase 1 waveLINE-001 study. Hematological Oncology. 2023;41(S2):571-2. DOI: https://doi.org/10.1002/hon.3164_427
Wang M, Eyre TA, Shah NN, Gouill SL, Dreyling MH, Vandenberghe E, et al. BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma. Journal of Clinical Oncology. 2023;41(16_suppl):TPS7587-TPS. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7587
Phillips TJ, Matasar M, Eyre TA, Gine E, Filézac De L’Étang A, Byrne B, et al. GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood. 2023;142(Supplement 1):3052-. DOI: https://doi.org/10.1182/blood-2023-173946
Andreadis B. Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma. 2024. DOI: https://doi.org/10.1182/hematology.2024000657
Center CoHM. Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. 2024.
Beigene. Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma. 2022.
Vienna MUo. Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma. 2024.
Beigene. Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader. 2022.
Beigene. A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies. 2021.
Therapeutics N. A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies. 2021.
Therapeutics N. A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies. 2022.
Abbvie. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies. 2023.
Inc AB. A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies. 2023.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
